Information  X 
Enter a valid email address

Vernalis PLC (VER)

  Print      Mail a friend       Annual reports

Tuesday 10 July, 2012

Vernalis PLC

Notice of Results

RNS Number : 2596H
Vernalis PLC
10 July 2012
 



10 July 2012

LSE: VER

 

Notice of Results for the Six Months Ended 30 June 2012

 

Vernalis plc today announces its half year results for the six months ended 30 June 2012 will be released on Wednesday, 1 August 2012. The earnings announcement will be distributed at 7:00 am (UK) and will be available to download from www.vernalis.com.

 

Following the results announcement, the Company will host a webcast and conference call for analysts and investors at 9:30 am (UK) on 1 August 2012.  Please contact Valerie Mugridge at Brunswick on +44 (0) 207 396 5325 for details.

 

-- ends --

 

Enquiries:

 

Vernalis Contacts:


Ian Garland, Chief Executive Officer

+44 (0) 118 938 0015

David Mackney, Chief Financial Officer

 


Nomura Code Securities Limited:

+44 (0) 20 7776 1200

Jonathan Senior


Christopher Golden

 


Brunswick Group: Jon Coles

 

+44 (0) 20 7404 5959

Taylor Rafferty: Rob Newman

 

+44 (0) 20 7614 2900

 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development.  The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough/cold market as well as eight programmes in its NCE development pipeline.  Vernalis has significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies.  The Company's technologies, capabilities and products are endorsed by collaborations with Endo, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

 

For further information about Vernalis, please visit www.vernalis.com

 

Vernalis Forward-Looking Statement

This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOREASXNESSAEFF